Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorProsser, H.en_US
dc.contributorPeck, K.en_US
dc.contributorDinh, D.en_US
dc.contributorRoberts, L.en_US
dc.contributorChandrasekhar, J.en_US
dc.contributorBrennan, A.en_US
dc.contributorDuffy, S.en_US
dc.contributorClark, D.en_US
dc.contributorAjani, A.en_US
dc.contributorOqueli, Ernestoen_US
dc.contributorSebastian, M.en_US
dc.contributorReid, C.en_US
dc.contributorFreeman, M.en_US
dc.contributorSajeev, J.en_US
dc.contributorTeh, A.en_US
dc.description.abstractAims The use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II-receptor blockers (ARBs) post-myocardial infarction (MI) is supported by evidence based on trials performed in the thrombolysis era. This was prior to primary percutaneous coronary intervention (PCI) being routine practice, and with little direct evidence for the use of these medications in patients with preserved left ventricular (LV) function. This study sought to determine whether there is an association between ACEi/ARB use after PCI for acute coronary syndrome (ACS) and long-term all-cause mortality, with a particular focus on patients with preserved LV function. Methods This multicentre, observational study evaluated prospectively collected data of 21,388 patients (> 18 years old) that underwent PCI for NSTEMI and STEMI between 2005 and 2018, and were alive at 30 day follow-up. Results In total, 83.8% of patients were using ACEi/ARBs. Kaplan–Meier analysis demonstrated ACEi/ARB use was associated with a significantly lower mortality in the entire cohort (15.0 vs. 22.7%; p < 0.001) with a mean follow-up of 5.58 years; and independently associated with 24% lower mortality by Cox proportional hazards modelling (HR 0.76, CI 0.67–0.85, p < 0.001). ACEi/ARB therapy was also associated with significantly lower mortality in patients with reduced or preserved LV function, with greater survival benefit with worse LV dysfunction. Conclusion ACEi/ARB therapy post-PCI is associated with significantly lower long-term mortality in patients with reduced and preserved LV function. These findings provide contemporary evidence for using these agents in the current era of routine primary PCI, including those with preserved EF.en_US
dc.description.provenanceSubmitted by Gemma Siemensma ( on 2022-08-19T01:58:10Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma ( on 2022-10-25T01:52:13Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2022-10-25T01:52:13Z (GMT). No. of bitstreams: 0 Previous issue date: 2022en
dc.titleRole of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction.en_US
dc.typeJournal Articleen_US
dc.bibliographicCitation.titleClinical Research in Cardiologyen_US
dc.subject.healththesaurusANGIOTENSIN RECEPTOR BLOCKERSen_US
dc.subject.healththesaurusHEART FAILUREen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.